PGDx elio tissue complete CDx lands FDA clearance for melanoma BRAF testing

Personal Genome Diagnostics (PGDx) has brought its elio® tissue complete CDx to advanced melanoma, giving oncologists and dermatologic oncology teams a new route to BRAF mutation testing with speed and confidence, according to an announcement covered by Inside Precision Medicine.

The assay is a tissue-based companion diagnostic. It targets BRAF testing in advanced melanoma, where identifying BRAF mutation status determines eligibility for targeted BRAF-inhibitor therapy. Turnaround confidence and speed are the two practical claims the company puts at the center of the launch.

What does the new CDx change for melanoma care?

BRAF mutation status drives therapy selection in advanced melanoma. Patients whose tumors carry a BRAF V600-series alteration can be routed to targeted therapy rather than immunotherapy alone, so the diagnostic step sits directly on the treatment decision path. A tissue-based CDx that returns results quickly reduces the gap between biopsy and first dose.

PGDx positions elio tissue complete CDx as an answer to that gap. The company frames the product around faster reporting and greater confidence in the result — the two friction points clinicians cite most often when tissue is limited or the patient is progressing.

How does it fit the dermatology workflow?

For dermatologists who manage advanced melanoma patients, the practical value sits in the diagnostic handoff. A companion diagnostic cleared for BRAF testing standardizes what might otherwise vary across send-out labs. That consistency matters when the result gates access to a targeted agent.

The product also fits a broader trend: molecular profiling of melanoma has moved from academic centers into routine community practice, and assay developers are competing on turnaround time as much as on analytical performance. PGDx is betting that a tissue-complete workflow — one that works with the sample already in the pathology lab — beats approaches that demand additional tissue or repeat biopsies.

What comes next?

The melanoma clearance adds a high-volume indication to the elio platform's CDx portfolio, and it signals PGDx's intent to compete in the companion-diagnostic segment for skin cancers. Clinicians will now be watching for real-world turnaround data and for adoption across the community oncology settings where most advanced melanoma patients receive care.